Annovis Receives NYSE Approval for Compliance Plan
Friday, June 20, 2025
Annovis Bio, Inc., a late-stage clinical drug platform company focused on developing treatments for neurodegenerative conditions such as Alzheimer's and Parkinson's disease, has confirmed that the New York Stock Exchange (NYSE) has accepted its proposed plan to regain compliance with the exchange’s listing standards.
The NYSE has given Annovis 18 months from 26 March 2025 to meet the necessary requirements related to minimum market capitalisation and shareholders’ equity. During this period, the company must submit quarterly updates to demonstrate progress.
Annovis expects its shares to remain listed on the NYSE throughout the compliance period, provided it continues to follow the plan and meet other listing conditions. This development does not impact the company’s operations, business activities, or its reporting obligations with the U.S. Securities and Exchange Commission.
Source: globenewswire.com
